Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2016 May 27;15(8):1809–1822. doi: 10.1158/1535-7163.MCT-15-0688

Figure 3. MLN8237 and MLN8237/eribulin combination reduces metastases in vivo.

Figure 3

A Quantification of size and number of pulmonary metastases as in (C). B Quantification of mammary tumor growth in MDA-MB-231LN-xenografts based on bioluminescence imaging (average radiance, p/s/cm2/sr) normalized to initial tumor volume (before drug application) at time point zero, referenced as 100%; one-way ANOVA: vehicle vs. treatments at each time point. C–D Representative images of H&E and F-IHC staining of pulmonary tissue (metastases defined by the white outline based on H&E), or D Mammary MDA-MB-231LN-xenograft tumor with anti-Ki67/red, -pAKT/purple antibodies. Scale bar - 30μm E–F Quantification of F-IHC as in (C–D); multiple metastases/or tumors; 5–6 animals, n=3; % to control; one-way ANOVA: vehicle vs. treatments;